# Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

> **NCT01188278** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 173 (actual)

## Conditions studied

- Leukemia, Myeloid, Chronic-Phase (CML-CP)

## Interventions

- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT01188278
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2016-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188278, "Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01188278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*